Skip to content

Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.

by Mary Courtney Moore
Current opinion in investigational drugs (London, England : 2000) ()
  • ISSN: 1472-4472 (Print)
  • PubMed: 17086938


Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.

Cite this document (BETA)

Readership Statistics

4 Readers on Mendeley
by Discipline
50% Medicine and Dentistry
25% Pharmacology, Toxicology and Pharmaceutical Science
25% Biochemistry, Genetics and Molecular Biology
by Academic Status
25% Professor > Associate Professor
25% Lecturer
25% Student > Doctoral Student

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in